FibroBiologics (FBLG)

• Market cap: $78M
• 1 day: 10.84%
• 5 days: 4.17%
• 1 month: 0.45%
• 3 months: -31.82%
• 6 months: -57.94%
• Year to date: -92.27%
• 1 year: -92.27%
• 5 years: -92.27%
• 10 years: -92.27%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.

Employees: 8

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

157% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 7

138% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 8

22% more funds holding

Funds holding: 50 [Q2] → 61 (+11) [Q3]

4.84% more ownership

Funds ownership: 10.68% [Q2] → 15.53% (+4.84%) [Q3]

4% less capital invested

Capital invested by funds: $17.4M [Q2] → $16.8M (-$637K) [Q3]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 433% upside
• Avg. target: $13.60 504% upside
• High target: $16 611% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Rodman & Renshaw Elemer Piros 18% 1-year accuracy 2 / 11 met price target	433% upside $12	Buy Initiated	12 Dec 2024
D. Boral Capital Jason Kolbert 25% 1-year accuracy 38 / 150 met price target	611% upside $16	Buy Maintained	20 Nov 2024
HC Wainwright & Co. Matthew Caufield 24% 1-year accuracy 12 / 50 met price target	433% upside $12	Buy Reiterated	13 Nov 2024
EF Hutton Jason Kolbert 25% 1-year accuracy 38 / 150 met price target	611% upside $16	Buy Maintained	18 Oct 2024
Maxim Group Michael Okunewitch 33% 1-year accuracy 2 / 6 met price target	433% upside $12	Buy Initiated	24 Sept 2024